Medtronic lifts profit forecast on medical devices demand, new launches
Adds details on new launches in paragraphs 4-6, details on segment revenue in paragraphs 9 and 10
Aug 20 (Reuters) -Medtronic MDT.N slightly lifted the lower end of its annual profit forecast on Tuesday, banking on sustained demand for its medical devices and growthfrom its new launches.
Over the past few quarters, medicaldevice makers have been benefiting from elevateddemand for non-urgent surgeries, sincepatients are increasingly optingfor procedures deferred during the pandemic.
The company said it was expecting steady growth as it introduces new products and continues to make investments to support those launches.
Earlier this month, the company said it received FDA approval for its first disposable, all-in-one continuous glucose monitor, Simplera.
Medtronic has partnered with AbbottABT.N, and will integrate its continuous glucose monitoring sensors with Medtronic's insulin delivery systems.
Limited U.S. commercial release of its Evolut FX+ Transcatheter aortic valve replacement device was initiated during the quarter, the company said. The device is used to perform minimally invasive surgery for people with heart valve disease.
The company raised the lower end of its 2025 adjusted profit forecast to$5.42 per share from $5.40 earlier, keeping the upper end at $5.50.
Analysts on average were expecting profit of $5.44 for 2025, according to LSEG data.
Quarterly sales at Medtronic's heart devices unit, its biggest revenue driver, increased 5.5% to $3.01 billion, above analysts' estimate of $2.92 billion.
Sales at the company's diabetes unit, rose nearly 12% while sales at its neuroscience unit, rose 4.4%.
Medtronic posted adjusted profit of $1.23 per share for the first quarter, beating estimates of $1.20.
Reporting by Sriparna Roy and Puyaan Singh in Bengaluru; Editing by Sriraj Kalluvila, Devika Syamnath and Alan Barona
Related Assets
Latest News
Disclaimer: The XM Group entities provide execution-only service and access to our Online Trading Facility, permitting a person to view and/or use the content available on or via the website, is not intended to change or expand on this, nor does it change or expand on this. Such access and use are always subject to: (i) Terms and Conditions; (ii) Risk Warnings; and (iii) Full Disclaimer. Such content is therefore provided as no more than general information. Particularly, please be aware that the contents of our Online Trading Facility are neither a solicitation, nor an offer to enter any transactions on the financial markets. Trading on any financial market involves a significant level of risk to your capital.
All material published on our Online Trading Facility is intended for educational/informational purposes only, and does not contain – nor should it be considered as containing – financial, investment tax or trading advice and recommendations; or a record of our trading prices; or an offer of, or solicitation for, a transaction in any financial instruments; or unsolicited financial promotions to you.
Any third-party content, as well as content prepared by XM, such as: opinions, news, research, analyses, prices and other information or links to third-party sites contained on this website are provided on an “as-is” basis, as general market commentary, and do not constitute investment advice. To the extent that any content is construed as investment research, you must note and accept that the content was not intended to and has not been prepared in accordance with legal requirements designed to promote the independence of investment research and as such, it would be considered as marketing communication under the relevant laws and regulations. Please ensure that you have read and understood our Notification on Non-Independent Investment. Research and Risk Warning concerning the foregoing information, which can be accessed here.
